Union Therapeutics A/s

Antibiotx A/s

Rasmus Vendler Toft-Kehler

Morten Otto Alexander Sommer

Daniel Jean Jacques Simon

Emilie Flora Aurore Delavenne

Anne Katrine Toft-Kehler

Günter Ditzinger

Mads Jellingsoe

Philippe Andres

Matthias Manne Knopp

The present invention relates to halogenated salicylanilides, or pharmaceutically acceptable salts or esters thereof, for use in the treatment of an infection in a subject caused bybacteria, particularly ainfection. The halogenated salicylanilides are expected to be useful in the treatment ofassociated diseases includingassociated diarrhoea andassociated colitis.

Halogenated salicylanilides for treatinginfections

The invention relates to a halogenated salicylanilide selected from closantel, rafoxanide, oxyclozanide and niclosamide and derivatives thereof including salts, hydrates, esters and the like for use in the topical treatment or prevention of infections caused by Gram-positive bacteria such as, in particular, and, in particular. Grain positive bacteria treated with the halogenated salicylanilides exhibit a very low frequency of appearance of resistant mutants compared to commonly used topical antibiotics.

Antibacterial use of halogenated salicylanilides

The invention relates to a halogenated salicylanilide selected from closantel, rafoxanide, oxyclozanide and niclosamide and derivatives thereof including salts, hydrates, esters and the like for use in the topical treatment or prevention of infections caused by Gram-positive bacteria such asin particularandin particularGrain positive bacteria treated with the halogenated salicylanilides exhibit a very low frequency of appearance of resistant mutants compared to commonly used topical antibiotics.

The invention relates to a method of treating a viral infection caused by or associated with SARS-CoV-2 in a subject, the method comprising administering to the subject by inhalation intraorally and/or intranasally a therapeutically effective amount of a formulation comprising niclosamide, or a pharmaceutically acceptable salt thereof, and a cyclodextrin.

Niclosamide formulations for treating disease

The invention relates to a halogenated salicylanilide selected from closantel, rafoxanide, oxyclozanide and niclosamide and derivatives thereof including salts, hydrates, esters and the like for use in the topical treatment or prevention of infections caused by Gram-positive bacteria such as, in particular, and, in particularGrain positive bacteria treated with the halogenated salicylanilides exhibit a very low frequency of appearance of resistant mutants compared to commonly used topical antibiotics.

This invention relates to combination products comprising an amidine selected from dibromopropamidine and diminazene or a pharmaceutically acceptable salt or solvate thereof; and a tetracycline anti-bacterial agent. The combination products are suitable for use in the treatment of bacterial infections or diseases.

Combinations comprising dibromopropamidine or diminazene and a tetracycline anti-bacterial agent

The present invention relates to halogenated salicylanilides, or pharmaceutically acceptable salts or esters thereof, for use in the treatment of an infection in a subject caused bybacteria, particularly ainfection. The halogenated salicylanilides are expected to be useful in the treatment ofassociated diseases includingassociated diarrhea andassociated colitis.

Halogenated salicylanilides for treating clostridium infections

The invention relates to a halogenated salicylanilide selected from closantel, rafoxanide, oxyclozanide and niclosamide and derivatives thereof including salts, hydrates, esters and the like for use in the topical treatment or prevention of infections caused by Gram-positive bacteria such as, in particular, and, in particular. Gram positive bacteria treated with the halogenated salicylanilides exhibit a very low frequency of appearance of resistant mutants compared to commonly used topical antibiotics.

Growing community of inventors

Copenhagen, Denmark

Rasmus Vendler Toft-Kehler